GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...

The judgment is from a lawsuit first filed two years ago, in which AZ alleged breach of an agreement between the original developer of Zejula (niraparib) – Tesaro – which was acquired by GSK ...

Tesaro, and Zentalis; royalties from UpToDate, Wiley, and ASCO; continuing medical education payments from Advance Medical, CEA Group, and Clinical Care Options; fees for Innovio Data and Safety ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.